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Background: The optimal treatment for locally recurrent rectal cancer (LRRC) is still a
matter of debate. This study assessed the outcome of LRRC patients treated with multimo-
dality treatment, consisting of neoadjuvant radio (chemo-) therapy, extended resection, and
intraoperative radiotherapy.
Methods: One hundred and forty-seven consecutive patients with LRRC who underwent
treatment between 1994 and 2006 were studied. The prognostic values of patient-, tumor- and
treatment-related characteristics were tested with uni- and multivariate analysis.
Results: Median overall survival was 28 months (range 0-146 months). Five-year overall,
disease-free, and metastasis-free survival and local control (OS, DFS, MFS, and LC respec-
tively) were 31.5%, 34.1%, 49.5% and 54.1% respectively. Radical resection (R0) was ob-
tained in 84 patients (57.2%), microscopically irradical resection (R1) in 34 patients (23.1%),
and macroscopically irradical resection (R2) in 29 patients (19.7%). For patients with a radical
resection median OS was 59 months and the 5-year OS, DFS, MFS, and LC were 48.4%,
52.3%, 65.5% and 68.9%, respectively. Radical resection was signiﬁcantly correlated with
improved OS, DFS, and LC (P\ 0.001). Patients who received re-irradiation or full-course
radiotherapy survived signiﬁcantly longer (P = 0.043) and longer without local recurrence
(P = 0.038) or metastasis (P\ 0.001) compared to patients who were not re-irradiated.
Conclusions: Radical resection is the most signiﬁcant predictor of improved survival in
patients with LRRC. Neoadjuvant radio (chemo-) therapy is the best option in order to realize
a radical resection. Re-irradiation is feasible in patients who already received irradiation as
part of the primary rectal cancer treatment.
Key Words: Rectal cancer—Local recurrence—Multimodality treatment—IORT—Re-irradia-
tion.
The introduction of total mesorectal excision
(TME) surgery and neoadjuvant radio (chemo-)
therapy (RCT) has resulted in a decrease of the
incidence of locally recurrent rectal cancer (LRRC)
to below 10%.1–6 However, patients who do develop
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LRRC still have limited treatment options and sub-
sequent prognosis. Due to prior surgery, tumor
growth is not conﬁned to a speciﬁc compartment
lined by fascias, because these fascias have been
damaged during the primary surgery. Therefore
recurrences easily grow into surrounding compart-
ments. Radicality can often only be achieved by a
multicompartmental resection. These resections are
accompanied by high morbidity and mortality rates
up to 10%.7–9 Neoadjuvant treatment options are
often limited because the patients have already re-
ceived radio (chemo-) therapy during the treatment of
the primary tumor. Tissue tolerance for re-irradiation
is limited to approximately 30 Gray (Gy) due to dose
accumulation toxicity.10 Furthermore, it can be
hypothesized that a recurrent tumor shows a more
aggressive biological behavior. It has been demon-
strated that more than 50% of patients with LRRC
will develop a metastasis within 6 months after the
diagnosis of the local recurrence.11
The inherent poor prognosis often leads to a
nihilistic approach (with a high tumor-related mor-
bidity), depriving patients of a chance of cure.
However, curative treatment has improved slightly in
specialized centers over the years, due to the use of
neoadjuvant RCT, radical resection and in some
centers intraoperative radiotherapy (IORT). IORT,
either as electron-beam therapy (IOERT) or as
brachytherapy, enables accurate delivery of a radia-
tion dose to the tumor bed. Dose limitations of
normal tissue can be minimized either by temporary
removal out of the irradiation volume or by lead
shielding. The use of external beam irradiation
(EBRT) in combination with IORT allows local
delivery of a tumorcidal biological dose up to 80–
90 Gy.12,13
As LRRC patients constitute a highly heteroge-
neous group, often presenting with concomitant
metastatic disease, and randomized studies are diﬃ-
cult to perform. Most of the knowledge about the
treatment of LRRC patients is empirical and ob-
tained from centers able to accumulate suﬃcient
data. Since 1994, the Catharina Hospital has been a
national referral center for patients with LRRC in the
Netherlands.
This retrospective study of a large patient popula-
tion assessed whether intensive multimodality treat-
ment, consisting of neoadjuvant radiotherapy (often
combined with chemotherapy), extended resection,
and IORT was useful in locally recurrent rectal can-




From March 1994 to July 2006, 184 consecutive
patients with LRRC within the pelvis, without iden-
tiﬁed distant metastases at time of diagnosis, were
scheduled for treatment with curative intent. For most
patients this treatment comprised multimodality
treatment, but some patients in early years did not
receive neoadjuvant treatment. Multimodality treat-
ment consisted of neoadjuvant radio (chemo-) ther-
apy, extended surgery, and IOERT. Patients were
referred to our institution from 42 hospitals through-
out the Netherlands. Upon referral, all data about the
primary and recurrent rectal tumor were available.
Thirty-seven patients were excluded from further
analysis because of the following reasons: 27 patients
proved to have irresectable disease because of tumor
growth into S2 or higher (n = 20), intraperitoneal
metastases (n = 10), and inﬁltration into the neural
plexus, which extended beyond the infrapiriform
foramen (n = 2). Ten patients were excluded because
they had a history of metastasectomy. The remaining
147 patients form the basis of this study. Patients’
charts, operation, and pathology reports were re-
viewed in order to obtain patient demographics and
treatment history. After resection of the LRRC, most
patients returned to their initial hospital for follow-up.
Follow-up data could be completed in all patients ei-
ther bymedical record review or by contacting patients
or their treating physicians by phone. Median follow-
up time for survivors was 34.0 months (range 6–
146 months). Our institutional review committee ap-
proved this analysis and waived informed consent,
because of the retrospective nature of the study.
Preoperative Evaluation
The local recurrences were discovered by routine
follow-up or symptoms. In most patients histological
conﬁrmation could be obtained by either direct or
computed tomography (CT)-guided biopsy. Progres-
sive growth on repeated magnetic resonance imaging
(MRI) or CT scans, especially in combination with
increased carcino-embryonic antigen level or positive
positron emission tomography (PET), was sometimes
considered as suﬃcient evidence for the diagnosis of a
local recurrence. All patients received a CT and/or a
MRI of the pelvis in order to assess the localization of
the recurrence and the extent of growth into sur-
rounding structures. In order to exclude disseminated
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disease patients underwent a liver ultrasound and a
chest X-ray and since the year 2000 a CT scan of the
chest and abdomen, in diﬃcult cases supplemented
with a PET scan.
Neoadjuvant Therapy
Neoadjuvant treatment regimen has changed over
the years, because of changes in treatment protocol.
In the early years (1994–1999), patients received
preoperative radiotherapy alone as external beam
radiation therapy (EBRT) with a dose of 50.4 Gray
(Gy), five times a week in 28 doses of 1.8 Gy. If the
patient had already received radiotherapy for the
primary tumor, no re-irradiation was given to the
recurrent tumor. In 1997, re-irradiation (30.6 Gray,
five times a week in 17 doses of 1.8 Gy) was intro-
duced in previously irradiated patients. EBRT was
delivered with a linear accelerator (10 MeV) by using
a three-field technique, utilizing one posterior and
two lateral portals. The pelvic field borders were: the
lateral borders extending 1–1.5 cm lateral of the bony
pelvis, the cranial borders being the promontory (L5–
S1), the caudal border was below the obturator
foramen. The dorsal border encompassed the sacrum
and the anterior border was chosen in such a way that
the initial tumor region was widely covered. If the
local recurrence was low seated, the perineum was
included in the radiation volume. If necessary, a
spacer was placed and a stoma was constructed. The
spacer was placed to displace the small bowel out of
the pelvis as much as possible. A biological spacer
like the omentum or the distal sigmoid was preferred
and if not feasible an artificial spacer (mamma
prosthesis) was used instead.
Since 1999, patients received neoadjuvant radio-
chemotherapy instead of radiotherapy alone. From
1999 until 2004, this consisted of 5-FU (350 mg/m2/
d) combined with leucovorin (20 mg/m2/d) during the
ﬁrst 5 days of re-irradiation or during the ﬁrst and
last 5 days of full course radiotherapy. Since 2004,
patients received either capecitabine (2 · 825 mg/m2/
d) 5 days a week for three weeks combined with ox-
aliplatin (50 mg/m2) on day 1, 8, and 15 or continu-
ous capecitabine (2 · 825 mg/m2/d) 5 days a week
alone. No adjuvant chemotherapy was administered,
as this was not part of treatment guidelines in the
Netherlands.
Surgery
Surgery was planned 8–10 weeks after completion
of EBRT. At the start of the laparotomy, the abdo-
men was carefully checked for liver, nodal, or peri-
toneal metastases. In all patients a radical resection
was intended. In order to obtain this, resection with
extended circumferential margins was necessary.14
The different surgical procedures are described in
Table 1. Radicality of resection was deﬁned as fol-
lows: a R0 resection had free surgical margins, a R1
TABLE 1. Patient and treatment characteristics
No. of patients
(n = 147)










First LR 133 (90.5)
Second LR 11 (7.5)
Third LR 3 (2.0)
Median interval primary-recurrent
surgery in months (range)
28 (3–207)
Type of primary surgery
Low anterior resection 80 (54.4)
Abdominoperineal resection 44 (30.0)
Rectosigmoid resection 18 (12.2)
Exenteration 2 (1.4)
Local procedure 3 (2.0)
Type of LRRC surgery
Low anterior resection 26 (17.7)
Abdominoperineal resection 48 (32.7)
Abdominotranssacral resection 39 (26.5)
Pelvic exenteration 17 (11.6)
Nonanatomic 17 (11.6)
EBRT for primary tumor
No
-EBRT for LRRC (FC) 66 (44.9)
-no EBRT for LRRC 3 (2.0)
Yes
-EBRT for LRRC (RI) 57 (38.8)
-no EBRT for LRRC 21 (14.3)
Neoadjuvant treatment for LRRC
No 24 (16.3)
RI without chemo 13 (8.9)
RI with chemo 44 (29.9)
FC without chemo 23 (15.6)











Values in parentheses are percentages unless indicated otherwise.
LR, local recurrence; LRRC, locally recurrent rectal cancer;
EBRT, external beam radiation therapy; Gy, Gray; RI, re-irradi-
ation; FC, full-course radiotherapy.
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resection had focally microscopically involved mar-
gins, and a R2 was deﬁned as more than 1 cm2 in-
volved margins, in most cases macroscopically visible
tumor was left behind. As specimens of locally
recurrent cases had no clearly deﬁned anatomical
borders, any free margin was considered as R0.
Intraoperative Radiotherapy
From 1994 until 2004, IOERT was given in a
dedicated radiotherapy suite. In 2004–2005, a mobile
unit was used in the operating theatre (Mobetron,
Intraop). Since 2006 IOERT was delivered in a ded-
icated operating room using a fixed accelerator; an
Elektra SL-25 linear accelerator with an in-house-
developed fixed applicator system. The accuracy of
dose delivery with this system is within the range of
±5%. The applicator diameter was chosen in such a
way that it covered the area at risk within a margin of
±1 cm. If necessary, bolus material was used to en-
sure sufficient surface dose at the area at risk for
possible residual tumor. The outcome of frozen sec-
tions taken during surgery determined IOERT dose
and target. When negative, 10 Gy was administered,
when positive with microscopic residual disease
12.5 Gy, with macroscopic residual disease (\2 cm2)
15 Gy was applied, and when positive with gross
residual disease ([2 cm2), 17.5 Gy was delivered. The
IOERT dose was speciﬁed on the 90% isodose along
the central beam axis. The depth of potential tumor
involvement of the area at risk was estimated to select
the energy needed to obtain an isodose of 90%
±1 cm beyond this tumor involvement. The energy
being used ranged from 6 to 18 MeV, corresponding
to an isodose depth of 1.4–2.8 cm, depending on the
diameter of the applicator (5–9 cm), the bevel end of
the applicator (0–30), the need of bolus material,
and the angle between applicator and surface to be
irradiated. Eleven patients did not receive IOERT: six
patients had excessive blood loss, in three patients no
area at risk could be identified, one patient already
received IOERT as part of the primary treatment,
and in one patient the risk for morbidity was too
high.
Statistical Analysis
Survival time was calculated from the LRRC
resection date until the last follow-up attendance or
until death. Time to recurrence, either local (within
the pelvis) or distant, was calculated from the
LRRC resection date until the histological or evi-
dent radiological presence of a local or distant
recurrence. Overall, cancer-speciﬁc, disease-free, and
metastasis-free survival, and local control (OS, CSS,
DFS, MFS, and LC, respectively) curves were con-
structed using the Kaplan–Meier method. Differ-
ences in observed survival between groups were
tested for statistical significance using log-rank
testing. Factors of which the P-value was less than
0.10 in the univariate analysis were included in the
multivariate analysis. Multivariate analysis was
performed using the Cox proportional hazards
regression model. Relations between various
parameters were analyzed using the v2 method. A
difference was considered statistically signiﬁcant if
P £ 0.05 (two-sided). Statistical analyses were per-
formed using the SPSS statistical software program
(SPSS for Windows Release 15.0, SPSS Inc, Chi-
cago, IL, USA).
RESULTS
Patient and Treatment Characteristics
Details of the patients and treatment are listed in
Table 1. Median anaesthesia time, including time
for IOERT, was 375 min (range 170–660 min).
Median blood loss was 4750 ml (range 420–
34,000 ml). Median hospital stay was 19 days (range
2–105 days). Mortality rate within 1 month after
operation was 4.8% (n = 7), and within 3 months it
was 8.2% (n = 12). During hospital admission, 95
complications were observed, in 86 patients (58.5%,
Table 2). Twenty-nine patients experienced urinary
retention, requiring prolonged catheterization. An-
other common complication was a pelvic abscess
(n = 22), needing a re-intervention in the majority
of patients. For the long-term complications, stan-
dardized questionnaires were regularly sent to the
surviving patients (EORTC QLQ C 30 and, CR 38,
and a more speciﬁc postoperative surgical morbidity
questionnaire of our own design). We found that
patients experienced long-term complications
(Table 2) to some extent but, with the increase of
time since the operation, the complaints decreased.
We did not ﬁnd any differences with regard to
morbidity for the various IORT doses. However,
the number of the higher doses was too low for a
statistical analysis.
Univariate Analysis
Median overall survival was 28 months (range 0–
146 months). Actuarial 5-year OS, CSS, DFS, MFS,
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and LC were 31.5%, 38.6%, 34.1%, 49.5%, and
54.1% respectively. For patients with a R0 resection,
median OS was 59 months and actuarial 5-year OS,
CSS, DFS, MFS, and LC were 48.4%, 57.5%,
52.3%, 65.5%, and 68.9%, respectively.
Patient-, primary tumor treatment-, and recur-
rence treatment-related factors were analyzed in
relation to 3-year overall survival, local control,
and metastasis-free survival (Table 3). Radical
resection was correlated with signiﬁcantly better OS
(Fig. 1), CSS, LC (Fig. 2), and MFS (Fig. 3) (all
P\ 0.001). Patients who received re-irradiation or
full-course radiotherapy as part of the treatment of
LRRC survived signiﬁcantly longer (P = 0.043)
and longer without local recurrence (P = 0.038) or
metastasis (P\ 0.001) compared to patients who
were not re-irradiated. Patients who had neoadju-
vant radio (chemo-) therapy experienced fewer
metastases (P\ 0.001), but did not survive longer
(P = 0.170) than patients who did not receive
neoadjuvant treatment. Early tumor–node–metas-
tasis (TNM) stage was associated with increased OS
and MFS rates (P = 0.008 and P = 0.023,
respectively). If patients previously underwent an
anterior resection, they survived 20 months longer
without metastasis (P = 0.007) than patients who
underwent an abdominoperineal resection (APR) as
primary surgery, but no statistical difference was
found in OS (P = 0.107) or LC (P = 0.069). Pa-
tients who could be treated with LAR for the local
recurrence survived 1.5 times longer than patients
in whom a more extensive resection was required
(P = 0.013).
Multivariable Analysis
The most important factors inﬂuencing overall
survival were radicality of resection and stage of the
primary tumor (Table 4). After irradical resection the
hazard ratio (HR) for early death was 2.11 (CI 1.37–
3.24, P = 0.001). In patients with a stage II or III
primary rectal cancer the mortality risk was about
three times higher than in patients with stage I disease
(P = 0.014 and P = 0.008, respectively). Patients
who had to undergo a more extensive resection for
LRRC had a signiﬁcantly worse prognosis (HR 2.11,
CI 1.09–4.08, P = 0.027) than patients only needing
a LAR. No signiﬁcant survival difference was found
for neoadjuvant radiotherapy. In the multivariable
analysis for local control, radical resection was the
only signiﬁcant factor (P = 0.001). The results of the
multivariable analysis for metastasis-free survival are
displayed in Table 5.
Factors Inﬂuencing Radicality of Resection (Table 6)
As our results showed radicality of resection to be
the most important predictor for survival, we decided
to analyze which factors were of inﬂuence on the
achievement of a radical resection. Neoadjuvant
treatment increased the radical resection rate; in pa-
tients who received radiotherapy (either full course or
re-irradiation) or radiochemotherapy signiﬁcantly
more radical resections were performed than in
patients who did not. After previous anterior resec-
tion, the achievement of a radical resection of the
LRRC was 20% higher than after previous abdomi-
noperineal resection (P = 0.044). No pain at time of
TABLE 2. Postoperative complications by type of neoadjuvant therapy
Total (n = 149) No (n = 24) Re-irradiation (n = 57) Full course (n = 66)
Postoperative
No 61 9 22 30
Urinary retention 29 4 13 12
Abscess 22 2 11 9
Wound infections 17 2 5 10
Sepsis 6 0 4 2
Urinary tract infection 5 0 2 3
Ileus 4 2 1 1
Haemorrhage 3 0 2 1
Venous embolus 3 2 1 0
Fistula 2 1 0 1
Urinary leakage 2 1 1 0
Pneumonia 2 0 1 1
Late postoperative
Lower extremity neuropathy 32 4 12 16
Ureter stenosis 8 0 4 4
3-month mortality 12 2 4 6
Values are absolute numbers.
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diagnosis was also correlated with a higher rate of
resections with a negative margin (P = 0.030).
Patterns of Failure
Median time to local recurrence was 13 months
(range 1–87 months) and to metastasis 11 months
(range 1–86 months). Thirty patients (20.4%) devel-
oped metastases within 1 year, and 22 (15.0%) had a
local recurrence within 1 year. In the long term,
around 50% developed a local recurrence or a
metastasis (Figs. 2 and 3). Twenty-three patients
survived more than 5 years (median 82 months;
range 64–146 months). Of these patients, 7 died of
the disease, 2 died of another cause, and 14 are cur-
rently alive with no evidence of disease.
DISCUSSION
This retrospective study of a large patient popula-
tion assessed whether intensive multimodality treat-
ment was useful in locally recurrent rectal cancer
patients. Furthermore, the role of re-irradiation was
determined. Multimodality treatment for LRRC has
been described as the most encouraging method to
improve survival and local control in selected pa-
tients.15,16 In the present study, an actuarial 5-year
TABLE 3. Univariate analysis of patient-, tumor-, and treatment-related factors
No. OS at 3 y* P LC at 3 y* P MFS at 3 y* P
All patients 147 (100) 43.8 57.0 53.1
Age (years)
\60 55 (37.4) 52.3 0.195 54.1 0.724 58.6 0.525
‡60 92 (62.6) 38.0 58.9 49.6
Gender
Male 84 (57.1) 46.5 0.822 56.7 0.636 54.8 0.332
Female 63 (42.9) 40.3 59.4 51.3
Stage of primary tumor
I 17 (11.6) 80.1 0.008 57.7 0.599 85.7 0.023
II 68 (46.3) 46.9 54.2
III 60 (40.8) 29.8 58.3 54.3
Unknown 2 (1.3) 39.4
Type of primary surgery
AR 98 (66.7) 46.0 0.107 64.3 0.069 58.4 0.007
APR 44 (30.0) 37.9 40.7 38.9
Interval
£2 years 68 (46.3) 48.7 0.728 57.9 0.917 60.6 0.221
[2 years 79 (53.7) 40.1 55.9 47.8
Symptoms at diagnosis
S0 40 (27.2) 49.9 0.275 59.6 0.031 55.0 0.363
S1 47 (32.0) 74.7 58.8
S2 58 (39.5) 47.7 43.3 46.1
Unknown 2 (1.3) 36.8
Dose EBRT for LRRC (Gy)
0 24 (16.3) 25.0 0.043 37.6 0.038 17.8 \0.001
30.6 (re-irradiation) 57 (38.8) 47.6 48.9 58.7
45–50 (full course) 66 (44.9) 49.3 69.0 61.2
Neoadjuvant RCT for LRRC
No 24 (16.3) 25.0 0.170 37.6 0.119 17.8 \0.001
RI without chemo 13 (8.9) 53.8 53.3 60.0
RI with chemo 44 (29.9) 44.9 46.9 54.8
FC without chemo 23 (15.6) 52.2 69.0 58.8
FC with chemo 43 (29.3) 47.5 69.1 64.2
Type of LRRC surgery
LAR 26 (17.7) 65.1 0.013 80.4 0.055 66.2 0.175
More extensive 121 (82.3) 39.4 51.4 50.0
Radicality of resection
R0 84 (57.2) 58.7 \0.001 74.9 \0.001 71.6 \0.001
R1 34 (23.1) 26.5 29.2 30.6
R2 29 (19.7) 24.1 28.5 18.8
Values in parentheses are percentages; *values are percentages of patients at three years after the operation. log rank test. OS, overall
survival; LC, local control; MFS, metastasis-free survival; AR, anterior resection; APR, abdominoperineal resection; S0, asymptomatic; S1,
symptomatic without pain; S2, symptomatic with pain; EBRT, external beam radiation therapy; LRRC, locally recurrent rectal cancer; Gy,
Gray; RCT, radio(chemo-) therapy; RI, re-irradiation; FC, full-course radiotherapy; LAR, low anterior resection; R0, microscopically
radical; R1 microscopically irradical; R2, macroscopically irradical.
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survival rate of 31.5% was achieved. This outcome
compares favorably to historical reports in which
patients were treated with surgery alone (24%)7 or
with palliative treatment (0%),17 but still remains
somewhat disappointing.
Several factors inﬂuencing the outcome of patients
with locally recurrent rectal cancer were identiﬁed.
The most important prognostic factor was radicality
of resection. In many studies with fewer patients the
importance of a radical resection was already re-
ported.16,18–22 In this study, in 57.2% of patients a
radical (R0) resection was accomplished. This per-
centage is consistent with the proportion of circum-
ferential margin-free resections reported in the
literature.21,23–27 Median overall survival (OS) and
cancer-speciﬁc survival (CSS) after R0 in this study
were 59 and 76 months, respectively. This compares
favorably to previous studies, which report survival
ranging from 17 to 50 months.7,9,22,28–31 Unlike the
ﬁnding of other authors32 that a difference may be
found after gross or microscopic residual disease we
did not ﬁnd a difference in oncological outcome after
R1 or R2 resection (Table 2). The major variable was
a tumor-free margin. This may be the result of the
fact that even minor residual disease represents an
aggressive tumor type in our series after intensive
neoadjuvant treatment. Another explanation may be
the difference in staging. In our R0 group more pa-
tients with close margins were present, leaving worse
patients in the R1 group.
Another important factor with a positive inﬂuence
on the outcome was re-irradiation. After re-irradia-
tion signiﬁcantly more radical resection could be
performed (64.9 versus 29.2%, P = 0.004) and a
signiﬁcantly better metastasis-free survival (MFS) (at
3 years: 58.7 versus 17.8%, P\ 0.001) was observed
compared to surgery alone in patients who had been
irradiated for their primary tumor. Other studies
report a lower rate of R0 resections when using sur-
gery alone.33–35 These ﬁndings stress the need for
renewed radiotherapy in patients who have previ-
ously been irradiated. Our data suggest that re-irra-
diation even in combination with chemotherapy and
intraoperative irradiation boost can be applied safely
and may result in a considerable survival beneﬁt and
even cure rate. The major concern of re-irradiation is
FIG. 1. Overall survival (OS) analysis. ALL, all patients
(n = 147); R0, radically resected patients (n = 84); R1–R2, ir-
radically resected patients (n = 63). R0 patients had a signiﬁcantly
better OS than R1–R2 patients (P\ 0.001).
FIG. 2. Local control (LC) analysis. ALL, all patients (n = 147);
R0, radically resected patients (n = 84); R1–R2, irradically re-
sected patients (n = 63). R0 patients had a signiﬁcantly better LC
than R1–R2 patients (P\ 0.001).
FIG. 3. Metastasis-free survival (MFS) analysis. ALL, all patients
(n = 147); R0, radically resected patients (n = 84); R1–R2, ir-
radically resected patients (n = 63). R0 patients had a signiﬁcantly
better MFS than R1–R2 patients (P\ 0.001).
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the fear of toxicity.24,36 However, as conﬁrmed by
others, patients can undergo re-irradiation with an
additional dose of 30–40 Gy with acceptable risks,
provided that the small intestine is located outside the
irradiation field and the interval between previous
irradiation and re-irradiation is more than
6 months.10,26,37–39 As we found earlier,14 the inten-
sive treatment brings along complications. However,
it is difﬁcult to ﬁnd out if these complications are due
to the tumor itself or due to the treatment. In the
perspective of severe symptoms of untreated locally
recurrent rectal cancer, the intensive multimodality
treatment is justiﬁed.
Other studies found a beneﬁt of the addition of
chemotherapy to the neoadjuvant radiotherapy.26,40
However, no statistically signiﬁcant difference be-
tween radiotherapy and radiochemotherapy was
demonstrated in our study. This might be due to
small patient numbers.
Furthermore, higher TNM stage of the primary
rectal cancer was an important negative prognostic
factor. It did not inﬂuence local control, but was a
signiﬁcant predictor of OS and MFS on both uni-
variate and multivariable analysis. These ﬁndings
suggest that positive lymph nodes are representative
of further metastatic spread of the disease at the time
of primary tumor resection. Vermaas et al.30 and
Hruby et al.41 reported similar results. Primary node-
positive disease resulted in a signiﬁcant worse prog-
nosis (P = 0.0009 and P\ 0.001, respectively). This
might be an indication to deliver adjuvant chemo-
therapy after LRRC resection in order to control or
prevent systemic disease.




R1 + R2 2.11 (1.37–3.24) 0.001
Stage of primary tumor
I 1
II 3.00 (1.25–7.19) 0.014
III 3.28 (1.37–7.88) 0.008
Dose EBRT for LRRC (Gy)
0 1.17 (0.67–2.03) 0.588
30.6 (RI) 0.94 (0.58–1.54) 0.818
45–50 (FC) 1
Type of LRRC surgery
LAR 1
More extensive 2.11 (1.09–4.08) 0.027
Values in parentheses are 95% conﬁdence intervals. R0, micro-
scopically radical; R1 microscopically irradical; R2, macroscopi-
cally irradical; EBRT, external beam radiation therapy; LRRC,
locally recurrent rectal cancer; Gy, Gray; RI, re-irradiation; FC,
full-course radiotherapy; LAR, low anterior resection.





R1 + R2 2.05 (1.13–3.72) 0.018
Stage of primary tumor
I 1
II 2.87 (0.85–9.77) 0.091
III 3.41 (1.00–11.67) 0.050
Dose EBRT for LRRC (Gy)
0 2.24 (1.14–4.39) 0.019
30.6 (RI) 1.01 (0.52–1.97) 0.983
45–50 (FC) 1
Type of primary surgery
AR 1
APR 1.81 (1.00–3.24) 0.048
Values in parentheses are 95% conﬁdence intervals. R0, micro-
scopically radical; R1 microscopically irradical; R2, macroscopi-
cally irradical; EBRT, external beam radiation therapy; LRRC,
locally recurrent rectal cancer; Gy, Gray; RI, re-irradiation; FC,
full course radiotherapy; AR, anterior resection; APR, abdomi-
noperineal resection.
TABLE 6. Factors inﬂuencing radicality of LRRC resection
Radical Irradical P*
Gender
Male 46 (54.8) 38 (45.2) 0.614
Female 38 (60.3) 25 (39.7)
Age (years)
\60 30 (54.5) 25 (45.5) 0.731
‡60 54 (58.7) 38 (41.3)
Interval
£2 years 42 (61.8) 26 (38.2) 0.319
[2 years 42 (53.2) 37 (46.8)
Primary TNM stage
I 11 (64.7) 6 (35.3) 0.189
II 43 (63.2) 25 (36.8)
III 29 (48.3) 31 (51.7)
Type of primary surgery
AR 61 (62.2) 37 (37.8) 0.044
APR 19 (43.2) 25 (56.8)
Previous EBRT (Gy)
0 41 (59.4) 28 (40.6) 0.232
25 (short course) 20 (66.7) 10 (33.3)
45–50 (long course) 23 (47.9) 25 (52.1)
EBRT for LRRC (Gy)
No 7 (29.2) 17 (70.8) 0.009
30.6 (re-irradiation) 37 (64.9) 20 (35.1)
45–50 (full course) 40 (60.6) 26 (39.4)
Radio(chemo) therapy
No 7 (29.2) 17 (70.8) 0.008
Radiotherapy 21 (58.3) 15 (41.7)
Radiochemotherapy 56 (64.4) 31 (35.6)
Symptoms at diagnosis
S0 24 (60.0) 16 (40.0) 0.030
S1 33 (70.2) 14 (29.8)
S2 26 (44.8) 32 (55.2)
Values in parentheses are percentages. *v2 test. LRRC, locally
recurrent rectal cancer; AR, anterior resection; APR, abdomino-
perineal resection EBRT, external beam radiation therapy; Gy,
Gray; LRRC, locally recurrent rectal cancer; S0, asymptomatic; S1,
symptomatic without pain; S2, symptomatic with pain.
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Other publications showed only a trend towards
improved survival with a lower primary TNM
stage11,37 or no relation at all.18,21,25,40,42
Not all LRRC patients described in the literature
can be compared to those studied in this paper. For
example, van den Brink et al.11 described patients
from the Dutch TME trial who developed a LRRC.
They found an early metastasis rate that approxi-
mated 75%, with 40% of these patients already
having a distant metastasis at time of LRRC diag-
nosis. In contrast, the patients in this study were al-
ready screened for concomitant metastases before
they were referred to our hospital. Therefore, it is not
surprising that the number of early metastases was
lower in this study. Despite the favorable selection,
50% of these patients still developed metastases over
time (Fig. 3). The multimodality treatment used fo-
cuses primarily on local control. The relative high
rate of systemic disease may be an argument to in-
clude systemic treatment in the multimodality strat-
egy. If systemic treatment would be administered in a
neoadjuvant fashion, response to this treatment
might be used as a selection criterion for further
invasive procedures: local responders not developing
metastases may be better candidates for extended
surgery, whereas those who show local progression or
even develop metastases under chemotherapy could
be spared unnecessary extended surgery. The inten-
sive multimodality treatment is not intended to
compensate for macroscopically residual tumor.
Therefore, a R2 resection may be considered as a
treatment failure. However, at present there is still no
modality to discriminate reliably between tissue
ﬁbrosis with and without tumor cells. Excluding all
patients with severe ﬁbrosis would mean that a pro-
portion of these patients would have been denied a
potentially curative resection. Therefore, it is impos-
sible to avoid R2 resections, given the limitations of
preoperative staging.
Some comments can be made about this study. It
was a retrospective analysis, but the data have been
collected prospectively. Heterogeneity in terms of
neoadjuvant treatment was due to changes in treat-
ment perspectives (e.g., introduction of total meso-
rectal excision and preoperative radio(chemo-)
therapy in primary rectal cancer treatment) in this
long period of patient accrual. For example in the
early years of the study, re-irradiation was not con-
sidered to be a treatment option, but because of more
evidence of the feasibility of this approach in later
years,39 it was started in 1997. Furthermore, the
beneﬁt or advantage of IORT could not be discussed
in our study as no comparison was possible between
patients who received IORT and those who did not,
since nearly all patients received IORT (and those
who did not had speciﬁc reasons for it). Hashiguchi
and co-workers43 found a signiﬁcant survival beneﬁt
in patients who received IORT compared to patients
who did not (3-year survival rate of 43% versus 5%,
P = 0.0007). This was also conﬁrmed on multivari-
ate analysis. Several studies describe an increase of
the 5-year survival rate of 15% or more after the
introduction of IORT as a component of multimo-
dality treatment.32,44,45 However, the role of IORT
remains debatable.29,46 Careful delivery of IORT is
important. The ureters, blood vessels, soft tissue,
bone, and pelvic nerves are structures at risk of injury
from IORT.13,44,47,48 IOERT doses of 10–20 Gy are
the maximum tolerable doses when combined with
EBRT. Data from MGH showed that for primary
rectal cancer the combined use of high-dose preop-
erative EBRT, surgical resection, and IOERT was
tolerated well.13 However, in locally advanced
recurrent disease the complication rate was higher.
Nevertheless, Krempien et al.49 described very low
long-term complications in patients with locally ad-
vanced primary rectal cancer treated with TME,
IOERT, and pre- or postoperative EBRT. The 5- and
10-year actuarial incidences of ‡ grade 3 late com-
plications for the entire group were 9% and 13%,
respectively. IORT in combination with re-irradia-
tion leads to a high radiobiological dose and our data
support the assumption that this dose can be applied
safely. However, large prospective randomized con-
trolled studies are lacking.
As local re-recurrence is a great problem after
treatment for local recurrence, the administration of
high tumorcidal irradiation doses at the areas of risk
follows a sound radiobiological principle. The po-
tential contribution of IORT to the improved cure
rates reported by others has also been achieved in this
analysis.
In summary, in this patient population with a
generally poor prognosis, the use of multimodality
treatment and radical resection has resulted in a more
favorable prognosis. Due to the rarity of this entity
and the inability to perform randomized studies, the
additional values of radiochemotherapy (versus
radiotherapy), re-irradiation, and IORT (versus no
IORT) were not clearly identiﬁable. Further evalua-
tion is required. However, high rates of radical
resections have been reached, leading to a signiﬁ-
cantly improved survival in patients with LRRC.
Unfortunately, development of metastatic disease
remains a great problem. In the future, attention has
to be paid to better patient selection and appropriate
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systemic treatment in order to ameliorate prognosis
even further.
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